Shunsei Hirohata
Overview
Explore the profile of Shunsei Hirohata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
1242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hibi T, Hirohata S, Hisamatsu T, Kikuchi H, Takeno M, Sato N, et al.
Adv Ther
. 2024 Oct;
41(12):4476-4497.
PMID: 39412631
Introduction: Behçet's disease (BD) with intestinal, neurological (NBD), and vascular (VBD) manifestations often leads to poor outcomes. Infliximab is approved for the treatment of intestinal BD, NBD, and VBD in...
2.
3.
Lauvsnes M, Zetterberg H, Blennow K, Kvaloy J, Tjensvoll A, Maroni S, et al.
J Neurol
. 2024 Mar;
271(5):2926-2927.
PMID: 38520522
No abstract available.
4.
Hirohata S, Kikuchi H, Sawada T, Kuwana M, Kawachi I, Kirino Y, et al.
Intern Med
. 2023 Jun;
63(4):481-486.
PMID: 37344428
Objectives Chronic progressive neuro-Behcet's disease (CPNB) is characterized by progressive deterioration leading to disability. Methotrexate (MTX) has been shown to have beneficial effects on CPNB. However, while infliximab has been...
5.
Nagafuchi H, Kikuchi H, Ishibash H, Maeda H, Ogino H, Kirino Y, et al.
Mod Rheumatol
. 2023 Jan;
34(1):182-193.
PMID: 36658731
Objectives: This study aimed to develop clinical guidelines for the management of vascular Behçet's disease (BD) by the Behçet's Disease Research Committee of the Ministry of Health, Labour and Welfare...
6.
Tsukui D, Hirohata S, Kikuchi H, Uozaki H, Kono H
Clin Exp Rheumatol
. 2022 Jun;
40(8):1584-1587.
PMID: 35765997
Pulmonary involvement in vascular Behçet's disease (BD) (VBD) is a serious manifestation. Among the pulmonary manifestations, pulmonary embolism is considered a rare manifestation because deep vein thrombosis (DVT) has been...
7.
8.
Hirohata S, Nagai T, Tomita T
Clin Exp Rheumatol
. 2022 Jan;
40(11):2097-2102.
PMID: 35084325
Objectives: Transforming growth factor β activated kinase 1 (TAK1) has been found to mediate maladaptive tumour necrosis factor (TNF) signalling, leading to hyperactive downstream nuclear factor Kappa β (NF-κB) signalling....
9.
10.
Tono T, Kikuchi H, Sawada T, Takeno M, Nagafuchi H, Kirino Y, et al.
Mod Rheumatol
. 2021 Dec;
32(6):1146-1152.
PMID: 34850090
Objectives: Approximately 30-60% of Behçet's disease patients exhibit joint symptoms. The aim of this study was to determine the clinical characteristics of such patients in Japan. Methods: This study retrospectively...